InduPro is a biotechnology company defining and harnessing inherent and induced proximity biology to unlock next-generation therapeutics in cancer and autoimmune diseases. The Company develops therapeutics against novel, tumor-selective targets and co-target pairs using bispecific antibodies including antibody drug conjugates (ADCs) and T cell engagers (TCEs), fueling a robust pipeline of first- and best-in-class programs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/24 | $85,000,000 | Series A |
Emerson Collective Euclidean Capital MRL Ventures Fund The Column Group  Vida Ventures | undisclosed |
